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Abstract
Background: Female hormones are known to play an important role in predisposition for many
infectious diseases. Recent work suggests there are gender effects in HIV/AIDS progression. Here
we ask whether the sex steroid hormone β-estradiol affects the replication of HIV-1 or the efficacy
of a common anti-retroviral drug, Stavudine (D4T).
Results: Human PBL were infected with HIV-1 in the presence or absence of combinations of sex
steroid hormones and the anti-retroviral drug, D4T. After seven days in culture, viral supernatants
were assayed for HIV-1 p24 protein. β-estradiol resulted in a modest inhibition of HIV-1 replication
of ~26%. However, 2 nM β-estradiol increased the amount of HIV-1 replication in the presence of
50 nM D4T from a baseline of 33% (+/- SE = 5.4) to 74% (+/- SE = 5.4) of control virus levels in the
absence of drug. Both results were statistically highly significant (p < 0.001). β-estradiol did not
increase the replication of a D4T-resistant strain of HIV in the presence of D4T. The effects were
unlikely to be due to general cell inhibition or toxicity because these concentrations of drug and
hormone cause no cytotoxicity in PBL as measured by trypan blue exclusion.
Conclusion:  β-estradiol inhibited both HIV-1 replication in primary human PBL and the
antiretroviral efficacy of D4T in PBL cultures. To optimize antiretroviral drug therapy, it may be
necessary to monitor patient hormonal status.
Background
Although there is evidence that viral load and anti-retrovi-
ral responses of women differ from those of men [1-3], lit-
tle is known about gender-specific effects of HIV infection
and treatments. Female hormones, including hormonal
contraceptives, are known to play an important role in
predisposition for many infectious diseases [4]. Whether
sex steroid hormones influence susceptibility to HIV-1
infection, severity of symptoms, risk of disease progres-
sion or interference of anti-retroviral therapy is not clear.
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However, a recent epidemiology study reported that the
HIV-1 viral load in blood is lower in women than in men
at similar stages of HIV-1 infection, suggesting that there
are gender effects in HIV/AIDS progression [5]. Further-
more, Lee et al reported that progesterone and Zidovudine
(AZT) synergistically inhibited HIV-1 replication in pri-
mary placental macrophages, possibly explaining why
AZT can inhibit maternal fetal transmission in the absence
of diminution of viral load [6].
Currently, viral load is used in conjunction with other
parameters (e.g., CD4 counts, drug resistance genotyping,
therapy history, appearance of side effects) to decide
whether to initiate or modify anti-viral therapy. The
observations that lower HIV-1 viral load may occur in
HIV-1 positive women prompt the concern that their
admission to anti-retroviral therapy under standard pro-
tocols could be inappropriately delayed, resulting in sub-
optimal efficacy in female patients. Consequently, it is
important to systematically determine the effects of sex
steroid hormones on HIV-1 replication, anti-retroviral
drugs and combinations of hormones and anti-retroviral
drugs. Here we ask whether the sex steroid hormone β-
estradiol influences the efficacy of the anti-HIV drug, Sta-
vudine (D4T).
Results
Hormone effect on anti-retroviral drugs in HIV-1 infection 
of PBL
2 nM β-estradiol depressed viral replication by ~26%.
Although D4T was titered to achieve ~50% inhibition in
preliminary experiments (not shown), when averaged
over 8 experiments, the estimated "half-maximal" D4T
concentration of about 50 nM resulted in an average
reduced viral replication to 33% of virus alone (VA, Table
1). In 8 of the 8 experiments summarized in Tables 1 &2,
virus levels in the presence of 2 nM β-estradiol in combi-
nation with 50 nM D4T were higher than in the presence
of 50 nM D4T alone (individual experiments not shown).
From the baseline average of 33% (of "VA") replication in
50 nM D4T, 2 nM β-estradiol increased HIV-1 replication
in the presence of D4T to 74% (of VA, SE = 5.4), for a dif-
ference of 41% (of VA).
To determine how the observed inhibition of drug efficacy
translates into increased drug levels required to achieve
half maximal virus inhibition in the presence of hormone,
D4T was titered in the presence of 2 nM β-estradiol. In the
presence of β-estradiol, an approximate 2 fold increase in
D4T concentration is required to inhibit HIV-1 replication
to levels seen in the absence of β-estradiol (compare
results for 50 nM D4T only to 100 nM D4T + β-estradiol,
Figure 1).
Cell viability
To determine whether the observed effects were caused by
non-specific effects on cell viability, cells were cultured
without virus infection but with 2 nM β-estradiol alone or
2 nM β-estradiol plus 1 μM D4T under the conditions
used for the experiments summarized in Tables 1 &2, and
stained with trypan blue on day 7 of culture. The results
show that the drugs and hormones were not toxic at the
concentrations tested, as presented in Table 3, even
though the concentration of D4T was over a log greater
than the concentration used for the data presented in
Tables 1 &2.
Hormone concentration dependence of D4T efficacy
Measurement of the effect of different concentrations of β-
estradiol on D4T efficacy suggests that the reduction in
efficacy titers over physiologically active levels of β-estra-
diol (Figure 2). For statistical analysis, the data were strat-
ified into "no response" (0 & 0.4 nM β-estradiol and
"response" (2, 10 & 50 nM β-estradiol) groups. The mean
difference between response and no response in this
experiment on 2 donors using 100 nM D4T was ~15 (per-
cent of virus alone), which was statistically highly signifi-
cant (p ≤ 0.0025). By way of contrast, similar titration of
progesterone (from 0.2 nM to 100 nM) in the presence of
D4T detected no effect of progesterone on D4T efficacy
(Figure 3). Progesterone alone at these same concentra-
tions also has no effect on HIV replication in PBL (data
not shown).
To determine the time course of the observed effects, HIV-
infected PBL were cultured in the presence or absence of
50 nM D4T, 2 nM β-estradiol, or both together as above.
Supernatant from the indicated days was analyzed for p24
Ag (Figure 4). The virus titers increased with time; how-
ever, the relative replication of virus in different arms
remained the same at all of the time points tested after day
4, although the differences between each group became
larger at later times.
Table 1: Effects of 2 nM β-estradiol on HIV replication in the 
presence and absence of 50 nM D4T*
Mean normalized pg/ml (%)** Standard Error
virus alone (VA) 100 5.4
β-estradiol 74 5.4
D4T 33 5.4
D4T+β-estradiol 74 5.4
no virus control 3.9 6.9
*Data presented represents the combined results of 8 independent 
experiments on PBL from 8 different donors. For each experiment all 
data points were the averages of three cultures wells run in triplicate. 
Virus replication was assessed by p24Ag ELISA of culture 
supernatants.
**Data is presented as the mean of least squares normalized to "virus 
alone."Retrovirology 2008, 5:82 http://www.retrovirology.com/content/5/1/82
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To determine whether the observed effects involved a
mechanism specific to the anti-reverse transcription
action of D4T, we determined the responses of a D4T-
resistant HIV mutant (HIV-1-D4Tr) to 50 nM D4T and 2
nM β-estradiol, separately and in combination. As seen in
Figure 5, in the absence of D4T susceptibility, the
enhancement effect of β-estradiol in the presence of D4T
is abolished.
Discussion
Interestingly, although β-estradiol modestly inhibits HIV-
1 replication in PBL, it increases HIV-1 replication in the
Table 2: Statistical Significance of Observed Differences*
Δ** Standard Error T value p***
"β-estradiol" – "virus alone" -25.9 7.6 -3.4 0.0009
"D4T + β-estradiol" – "D4T alone" 41 7.6 5.4 < 0.0001
*Analysis of the dataset summarized in Table 1.
**Difference in raw percentages of data normalized to "virus alone."
***p = probability that the difference is zero.
Change in D4T concentration required to overcome the efficacy impairment caused by β-Estradiol Figure 1
Change in D4T concentration required to overcome the efficacy impairment caused by β-Estradiol. A series of 
D4T dilutions were applied to HIV-1 infected PBL with or without 2 nM β-estradiol. The viral concentrations were measured 
with p24 ELISA, then normalized to the viral concentration from HIV-1 alone control. The data presented represents averages 
and standard deviations (error bars) from experiments performed on 4 different donors, each run in duplicate. Stippled, β-
estradiol +D4T; clear, D4T alone.
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presence of a fixed amount of D4T, and this increase is
specifically dependent on the anti-retroviral effect of the
drug. Thus β-estradiol seems to decrease the efficacy of
D4T against HIV-1 infection of PBL. The data suggests that
the magnitude of the effect on D4T efficacy is such that
approximately at least a two fold increase in the concen-
tration of D4T would be necessary to overcome the effects
of the hormone.
β-estradiol increased the amount of HIV-1 replication in
the presence of D4T from a baseline of 33% (of VA, +/- SE
= 5.4) to 74% (+/- SE = 5.4), (Tables 1 &2, Figure 1 & Fig-
ure 2) whereas progesterone had little or no effect on viral
replication in the presence (or absence) of D4T (Figure 3).
The concentrations of D4T used here for viral inhibition
are within range of levels typically used for tissue culture
work [7-10] and have not been reported to cause signifi-
cant cytotoxicity. Nevertheless, we did test to see if the
combinations of drugs and hormones studied caused
detectable non-specific cytotoxicity in PBL. Even exces-
sively high concentrations of D4T (1 uM) caused no cyto-
toxicity in the presence or absence of β-estradiol, as
measured by trypan blue exclusion. β-estradiol alone also
caused no cytotoxicity (Table 2).
Table 3: Trypan blue resistance of PBL cultured with β-estradiol 
and/or D4T*
Treatments Trypan blue negative cells as %*
Donor 1 Donor 2
No treatment 91 85
β-estradiol 88 83
β-estradiol + D4T 86 82
D4T 87 80
*Cells were prepared as if for infection and harvested after 7 days of 
culture in the concentrations of β-estradiol and/or D4T indicated. 200 
cells total counted for each data point.
β-estradiol concentration vs. D4T efficacy Figure 2
β-estradiol concentration vs. D4T efficacy. Serial dilutions of β-estradiol were combined with 100 nM D4T and then 
added to the HIV-1 infected PBL. The viral concentrations were measured with p24 ELISA, then normalized to the viral con-
centration from the "HIV-1 alone" control. Data was obtained from duplicate cultures from each of two different donors. 
Error bars represent the averaged results for each donor.
0
10
20
30
40
50
60
70
80
00 . 421 05 0
Beta-Estradiol (nM)
P
e
r
c
e
n
t
a
g
e
 
o
f
 
"
H
I
V
-
1
 
a
l
o
n
e
"Retrovirology 2008, 5:82 http://www.retrovirology.com/content/5/1/82
Page 5 of 8
(page number not for citation purposes)
The mechanism by which β-estradiol promotes HIV repli-
cation in the presence of D4T remains unknown. How-
ever, we have observed β-estradiol has no (or minimal)
effect on HIV replication in the presence of the protease
inhibitor, Saquinavir (unpublished observations). The
finding that in the absence of D4T β-estradiol inhibits HIV
replication, whereas in the presence of D4T it enhances
HIV replication, strongly suggests that the mechanism of
the enhancement is D4T-specific. In confirmation of this,
we determined that β-estradiol has no effect on HIV repli-
cation in the presence of D4T when the HIV is resistant to
D4T. Thus, the observed enhancement is most likely on
the anti-retroviral efficacy of D4T. This is consistent with
β-estradiol inhibiting the concentration or activity of the
cellular enzymes used to phosphorylate D4T to its active
form, D4T-TP, but does not rule out a mechanism involv-
ing changes in drug influx or efflux. Experiments to
address these issues are currently ongoing in our labora-
tory.
The inhibition of antiretroviral drug efficacy by estrogen
may have implications for anti-HIV-1 drug therapies. The
studies presented here put forth the novel concept that at
any given plasma concentration of drug, the final efficacy
may be significantly affected by the hormone status of the
patient. Most likely, β-estradiol acts by modifying intrac-
ellular levels of the active form of D4T through mecha-
nisms which may include controlling drug influx or efflux
or, more likely, controlling the phosphorylation steps
which lead to the D4T-TTP active form of D4T [11,12].
Thus, monitoring of β-estradiol levels, which vary during
pregnancy, menstrual cycling and with hormone replace-
Progesterone concentration vs. D4T efficacy Figure 3
Progesterone concentration vs. D4T efficacy. Serial dilutions of progesterone were combined with 100 nM D4T and 
then added to the HIV-1 infected PBL. The viral concentrations were measured with p24 ELISA, then normalized to the viral 
concentration from the "HIV-1 alone" control. Data was obtained from duplicate cultures from each of two different donors. 
Error bars represent the averaged results for each donor.
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ment therapy and birth control, or monitoring intracellu-
lar levels of active drug may provide significant added
benefit over monitoring plasma levels of drug alone.
Methods
Cell Culture
PBMC were isolated from the peripheral blood of HIV
sero-negative donors (NIH Blood Bank) by Ficoll/
Hypaque density gradient centrifugation. After monocytes
were removed by adherence to the culture flasks, the
remaining cells, PBL, were stimulated with 2 μg/ml PHA
for 3 days to activate T cells before infection and either
used fresh, or stored in liquid nitrogen before infection.
The PBL cultures were maintained in 5% CO2 in complete
RPMI (phenol red free RPMI 1640, supplemented with
10% heat-inactivated, charcoal dextran stripped FBS (Inv-
itrogen, CA), 2 mM glutamine, 100 unit of penicillin per
ml, 100 ug of streptomycin per ml, 10 mM HEPES), and 5
half-maximal units per ml of human Interleukin-2
(Roche, NJ).
Virus
Wild type HIV was strain 9320, a low passage, AZT-sensi-
tive isolate (A018, D. Richman) cultured in PBMC [13]. A
highly AZT resistant strain of HIV-1 was obtained through
the AIDS Research and Reference Reagent Program (Ger-
mantown, MD), AZT Resistant HIV-1 (catalogue number
629). We determined that this strain was cross resistant to
D4T and referred to it in the text as "HIV-1-D4Tr." Stocks
of HIV-1/9320 and HIV-1-D4Tr (both of which are
Time course of viral replication in the presence or absence of D4T and/or β-estradiol Figure 4
Time course of viral replication in the presence or absence of D4T and/or β-estradiol. HIV-infected PBL were cul-
tured in the absence of drug and hormone, or in the presence of either 50 nM D4T or 2 nM β-estradiol, or the two together. 
Supernatants were harvested for p24 analysis on the indicated days. The data presented represent the results of infection of 2 
different donors, with each arm run in triplicate wells of a 24-well plate containing 2 million PBL. Error bars represent standard 
deviations.
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known to replicate in PBL) were normalized to p24 Ag
and tested for their ability to replicate in cultures of pri-
mary human microphages, in parallel with HIV-1 BAL
(positive control) and HIV-1 IIIB (negative control). Both
HIV-1/9320 and HIV-1-D4Tr strains replicated no better
than HIV-1 IIIB in macrophages (data not shown).
Hormones and anti-retroviral drugs
β-estradiol and progesterone and D4T were obtained from
Sigma (St. Louis, MO). D4T was obtained from the NIH
AIDS Research and Reference Reagent Program (German-
town, MD).
Measurement of Virus Replication
Activated PBL cells were exposed to HIV strain 9320 or
HIV-1-D4Tr for 2 hrs at 37°C at a concentration of 100
TCID50. Cells were then distributed into the appropriate
arms of the experiment and cultured in triplicate wells of
a 96 well plate at a concentration of 500,000 cells per well
or a 24 well plate at a concentration of 2,000,000 cells per
well in the same medium as for PBL culture. Cell superna-
tants were harvested on day 7 for analysis by HIV p24
ELISA (Perkin Elmer, MA). Each well was measured in sin-
glicate. Similar results were obtained whether or not 50%
of the supernatant of each well (including appropriate
hormone/drug concentrations) were replaced on day 3–4.
Statistics
Since the data were correlated, the PROC GLM in the SAS
system was utilized to conduct the ANOVA analyses of the
data while taking into consideration of the intra-correla-
tion structure of the data. For the data presented in Tables
1 &2, each observation was translated into pg units based
on the standard curve of the OD and pg reading. Then
they were normalized into percentages of the "virus
alone" data based on the average of the virus alone data
for that particular experiment. Each of the 8 experiments
was run in triplicate. A similar approach was used for the
data in Figure 2, except that only two separate donors
The effect of D4T and β-Estradiol on the replication of a D4T-resistant mutant of HIV Figure 5
The effect of D4T and β-Estradiol on the replication of a D4T-resistant mutant of HIV. PBL were infected in paral-
lel with wild type HIV-1 (strain 9320), open, or D4T-resistant HIV-1 (HIV-1-D4Tr), shaded, and were grown in the presence of 
either no added drug or hormone, 50 nM D4T alone, 2 nM β-estradiol alone, or the two together. Supernatants were har-
vested for p24 analysis on day 7. In each experiment infected cells were plated in triplicate wells of a 24 well plate, each con-
taining 2 million PBL, and the average replication determined normalized to virus alone ("VA). The data presented represent 
the averages of three independent experiments on independent donors. The error bars represent +/- one SD.
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(experiments) were tested and they were tested in dupli-
cate.
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